Immunitybio Inc - Asset Resilience Ratio
Immunitybio Inc (IBRX) has an Asset Resilience Ratio of 38.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Immunitybio Inc's Asset Resilience Ratio has changed over time. Check IBRX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Immunitybio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IBRX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $197.57 Million | 38.07% |
| Total Liquid Assets | $197.57 Million | 38.07% |
Asset Resilience Insights
- Very High Liquidity: Immunitybio Inc maintains exceptional liquid asset reserves at 38.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immunitybio Inc Industry Peers by Asset Resilience Ratio
Compare Immunitybio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
Annual Asset Resilience Ratio for Immunitybio Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Immunitybio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.67% | $6.38 Million | $382.93 Million | +1.47pp |
| 2023-12-31 | 0.20% | $1.01 Million | $504.45 Million | -0.50pp |
| 2022-12-31 | 0.70% | $2.54 Million | $362.36 Million | -28.30pp |
| 2021-12-31 | 29.01% | $136.01 Million | $468.91 Million | +1.39pp |
| 2020-12-31 | 27.62% | $61.15 Million | $221.38 Million | +2.37pp |
| 2019-12-31 | 25.25% | $36.14 Million | $143.12 Million | -6.25pp |
| 2018-12-31 | 31.51% | $57.33 Million | $181.95 Million | -10.13pp |
| 2017-12-31 | 41.64% | $104.28 Million | $250.44 Million | -18.47pp |
| 2016-12-31 | 60.11% | $190.84 Million | $317.50 Million | +27.86pp |
| 2015-12-31 | 32.25% | $118.31 Million | $366.85 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more